WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer, will present a corporate update at the upcoming Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 3:30 p.m. ET in Boston, Massachusetts.
